Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

383
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
383
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

2.8K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of an Oncology Hospital at Home Program on Health Care Costs.

Medical care·2026
Same author

A Seminal Shift in Prostate Cancer Detection?

The Journal of urology·2026
Same author

Cardiovascular Disease in a Population-Based Cohort of Prostate Cancer Patients With Long-Term Follow-Up.

Clinical genitourinary cancer·2026
Same author

Use of Hypofractionation Among Underserved Populations Undergoing Radiation Therapy for Cancer: Implications for Policy.

International journal of radiation oncology, biology, physics·2026
Same author

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

medRxiv : the preprint server for health sciences·2026
Same journal

Editorial Commentary.

Urology practice·2026
Same journal

Reply by authors.

Urology practice·2026
Same journal

The Impact of Patient-Provider Relationships on Prostate Cancer Screening: A Cross-Sectional Analysis of the All of Us Research Program.

Urology practice·2026
Same journal

Adjuvant Radiation Therapy Versus Initial Observation for Patients After Prostatectomy with Adverse Pathology: Have Findings from 3 Randomized Clinical Trials Influenced Clinical Practice?

Urology practice·2026
Same journal

National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Urology practice·2026
Same journal

Patient Trust and Medical Mistrust Toward Overactive Bladder Therapies: General Consumer Awareness and Perceptions.

Urology practice·2026
See all related articles

Related Experiment Video

Updated: Jul 19, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

707

Leveraging Outcomes Research to Optimize Prostate Cancer Care.

Brock O'Neil1, Matthew J Resnick1,2

  • 1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Urology Practice
|August 18, 2023
PubMed
Summary
This summary is machine-generated.

Integrating patient-reported outcome measures (PROMs) and decision aids into localized prostate cancer care can enhance patient decision-making. Tools like the Expanded Prostate Index Composite-Short Form (EPIC-SF) are recommended for tracking outcomes.

Keywords:
decision makingpatient preferenceprostatic neoplasmsquality of lifequestionnaires

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Experiment Videos

Last Updated: Jul 19, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

707
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Area of Science:

  • Urology
  • Oncology
  • Health Services Research

Background:

  • Localized prostate cancer treatment involves multiple options with varying side effects, making patient preference crucial.
  • Patient-reported outcome measures (PROMs) and decision aids can enhance shared decision-making and improve patient outcomes.
  • Current clinical practice faces barriers to integrating these valuable patient-centered tools.

Purpose of the Study:

  • To review the literature on PROMs and decision aids for localized prostate cancer management.
  • To discuss the importance and implementation challenges of these tools in clinical practice.
  • To recommend specific tools and strategies for successful integration.

Main Methods:

  • Systematic literature review of studies on PROMs and decision aids in localized prostate cancer.
  • Synthesis of key findings regarding the impact and utility of these tools.
  • Identification of barriers and facilitators for clinical implementation.

Main Results:

  • High-quality PROMs, such as the Expanded Prostate Index Composite-Short Form (EPIC-SF), are increasingly adopted in clinical settings.
  • Decision aids demonstrably improve patient knowledge, satisfaction, and reduce uncertainty.
  • Provider engagement and established office protocols can overcome implementation barriers.

Conclusions:

  • Incorporating PROMs and decision aids into clinical practice is essential for improving shared decision-making quality in prostate cancer care.
  • Thoughtful implementation strategies are necessary for the successful integration of these patient-centered tools.
  • The use of EPIC-SF is recommended for standardized outcome measurement in localized prostate cancer.